Company Projected Revenue: BioXcel Therapeutics Inc (BTAI)

BioXcel Therapeutics (BTAI) bases its strategy on AI-driven drug repositioning, betting its success on the expansion of Igalmi. The company's future sales trajectory visualizes expected revenues stripped of market emotion, where the 0.00 mark indicates the current state. However, a change in distributors is temporarily complicating logistics, while a rapid cash burn and regulatory risks pose a serious threat to the business's financial stability.

Company Expected Sales Volume: BioXcel Therapeutics Corp (BTAI) for 07/04/2022 - 09/19/2026

Summary analytical data breakdowns for BioXcel (BTAI)

- stock value and consensus price forecast:

Price Chart BioXcel Therapeutics Corp|BTAI - Average Forecast Price

- company stock exchange capitalization indicators:

Market Value BioXcel Therapeutics Corp|BTAI - Total Company Value

- balance sheet equity data:

Net Assets per Single Share BioXcel Therapeutics|BTAI - Total Stockholders' Equity|Market Capitalization to Book Value Ratio bioxceltherapeutics.com|BTAI - Company Balance Sheet Assets

- debt obligations and liquidity statistics:

Total Debt to Equity Ratio BioXcel Therapeutics|BTAI - Long-Term Liabilities to Capital|Short-Term Debt to Capital BioXcel Therapeutics|BTAI - Company Debts|Debts to Book Capitalization BioXcel Therapeutics, Inc.|BTAI - Long-Term Debt Volume|Company Short-Term Debt BioXcel Therapeutics|Quick Liquidity Indicator bioxceltherapeutics.com

- company profitability and valuation multiples indicators:

BTAI - Company Profit|Projected Future Earnings BioXcel Therapeutics|BTAI - Price to Earnings Ratio|Forward P/E Multiple bioxceltherapeutics.com|BTAI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioXcel Therapeutics Corp|BTAI - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months BioXcel Therapeutics|BTAI - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months bioxceltherapeutics.com|BTAI - Net earnings per one share growth for the current year|Earnings growth forecast for next year BioXcel Therapeutics

- sales and revenue data:

BTAI - Company Sales Revenue|Projected Sales Volume BioXcel Therapeutics Corp|BTAI - Price to Sales|Price-to-Projected Revenue Ratio BioXcel Therapeutics

General company analysis:BioXcel Therapeutics Inc

Product sample of BioXcel Therapeutics Inc

BioXcel Therapeutics (BTAI) possesses high scalability thanks to its AI platform for drug repositioning. This indicator reflects the market consensus regarding future cash flows, filling the time gaps between quarterly reports. Through this mechanism, investors assess the speed of commercializing digital developments. By analyzing the firm's sales volume potential, one can determine current market revenue expectations. The trend of this metric helps identify the asset's growth points in a timely manner.

Main competitors

Company Projected Revenue Jazz Pharmaceuticals Corp (JAZZ)|CYTK - Company Expected Sales Volume|Company Projected Revenue PTC Therapeutics Corp PTCT|Scholar Rock Inc. - Company Projected Revenue|CNTA - Company Projected Revenue|Company Sales Forecast Dyne Therapeutics (DYN)|EWTX: Projected Sales Volume|Company Sales Forecast Rapport Pharma RAPP|Company Future Sales Volume ALMS|Company Expected Sales Volume Zevra Therapeutics ZVRA|Projected Sales Volume CTNM|Company Projected Revenue LRMR (Larimar Therapeutics)|Projected Sales Volume CAPR (Capricor Therapeutics Inc.)|TRDA: Company Revenue Forecast|Channel Therapeutics Inc. - Projected Sales Volume|MNOV (medicinova.com) - Company Revenue Forecast|Serina Therapeutics (SER) - Company Projected Revenue|PMN - Company Future Sales|APUS (Apimeds Pharmaceuticals, Inc.) - Projected Sales Volume|AEON: Company Future Revenue|Projected Sales Volume NLSP|Company Future Sales Volume Bionomics BNOX|Projected Sales Volume HUGE (fsdpharma.com)|RETA (Reata Pharmaceuticals) - Company Expected Revenue